Novo Nordisk’s (NVO) Wegovy pill reached over 26,000 U.S. prescriptions in its second full week, signaling strong demand for the oral weight-loss treatment 1.
The prescription momentum could drive significant revenue growth for Novo Nordisk, which has dominated the 24 billion GLP-1 weight-loss market with its injectable Wegovy formulation.
Key Takeaways
- Wegovy pill hits 26,109 prescriptions in week ending January 23
- Strong trajectory from 3,071 prescriptions in first four launch days
- Barclays analysts called the launch “very strong”
Market reaction & context
The pill recorded 26,109 prescriptions for the week ended January 23, according to IQVIA data shared by analysts 2. This represents substantial growth from the 3,071 prescriptions recorded in the first four days after the January 5 launch and 18,410 prescriptions in the first full week 3.
The launch trajectory outpaces previous Novo Nordisk drug debuts, positioning the company to capture additional market share in the competitive obesity treatment space. Rival Eli Lilly’s (LLY) Zepbound injection has been gaining ground since its approval in late 2023.
Detailed analysis
The oral Wegovy formulation addresses a key patient preference for pills over injections, potentially expanding the addressable market significantly. Weekly prescription volumes have grown consistently since launch, suggesting sustained physician and patient adoption 4.
Analysts noted the strong debut compared to typical pharmaceutical launches, where prescription uptake often builds more gradually. The rapid acceleration indicates robust underlying demand and effective market positioning by Novo Nordisk’s sales force.
Outlook & analyst perspective
“The launch of the oral drug is very strong,” Barclays analysts said, based on the latest prescription tracking data 5. The firm’s assessment reflects growing confidence in the commercial potential of the pill formulation.
Healthcare data firm IQVIA’s prescription tracking provides real-time visibility into drug adoption patterns, making it a closely watched metric for investors and pharmaceutical companies. The consistent weekly growth trajectory suggests the oral Wegovy could become a significant revenue contributor for Novo Nordisk.
Investment implications
The strong prescription momentum reinforces Novo Nordisk’s leadership position in the obesity treatment market, where patient demand continues to outstrip supply capacity. Oral formulations typically command higher patient compliance rates than injectable alternatives, potentially driving longer treatment duration and higher lifetime value per patient.
Wall Street analysts view GLP-1 medications as transformative treatments with multi-billion dollar revenue potential, making prescription tracking data critical for investment decisions in the space.
Not investment advice. For informational purposes only.
References
1(January 30, 2026). “Novo’s Wegovy pill tracks over 26,000 prescriptions”. Reuters. Retrieved January 30, 2026.
2(January 30, 2026). “Novo’s Wegovy pill surpasses 26,000 prescriptions in second full week”. SRN News. Retrieved January 30, 2026.
3(January 23, 2026). “Novo’s Wegovy pill hits over 18,000 US prescriptions in strong debut”. WHTC. Retrieved January 30, 2026.
4(January 30, 2026). “Novo’s Wegovy pill surpasses 26,000 prescriptions in second full week”. MarketScreener. Retrieved January 30, 2026.
5(January 30, 2026). “Strong Start for Novo Nordisk’s Wegovy Tablet in the US”. MarketScreener. Retrieved January 30, 2026.